NO20040431L - New method for down-regulation of amyloid - Google Patents

New method for down-regulation of amyloid

Info

Publication number
NO20040431L
NO20040431L NO20040431A NO20040431A NO20040431L NO 20040431 L NO20040431 L NO 20040431L NO 20040431 A NO20040431 A NO 20040431A NO 20040431 A NO20040431 A NO 20040431A NO 20040431 L NO20040431 L NO 20040431L
Authority
NO
Norway
Prior art keywords
methods
amyloid
app
autologous
vaccination
Prior art date
Application number
NO20040431A
Other languages
Norwegian (no)
Other versions
NO335602B1 (en
Inventor
Martin Roland Jensen
Klaus Gregorius Nielsen
Peter Birk Rasmussen
Peter Koefoed
Florence Dal Degan
Original Assignee
Pharmexa As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/DK2002/000547 external-priority patent/WO2003015812A2/en
Application filed by Pharmexa As filed Critical Pharmexa As
Publication of NO20040431L publication Critical patent/NO20040431L/en
Publication of NO335602B1 publication Critical patent/NO335602B1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0007—Nervous system antigens; Prions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/385—Haptens or antigens, bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6068—Other bacterial proteins, e.g. OMP
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6087—Polysaccharides; Lipopolysaccharides [LPS]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6093—Synthetic polymers, e.g. polyethyleneglycol [PEG], Polymers or copolymers of (D) glutamate and (D) lysine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/64—Medicinal preparations containing antigens or antibodies characterised by the architecture of the carrier-antigen complex, e.g. repetition of carrier-antigen units
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Abstract

Det beskrives nye fremgangsmåter for bekjempelse av sykdommer som er kjennetegnet ved amyloid avleiring. Fremgangsmåtene angår generelt immunisering mot amyloid forløperprotein (APP) eller betaamyloid (AP). Immunisering utføres fortrinnsvis ved administrering av analoger av autologe APP eller AP, nevnte analoger er i stand til å indusere antistoffremstilling mot de autologe amyloidogene polypeptidene. Spesielt foretrukket som et immunogen er autolog AP som har blitt modifisert ved å introdusere et enkelt eller noen få fremmede, immunodominante og promiskuøse T-celleepitoper. Det beskrives også nukleinsyrevaksinering mot APP eller AP og i tillegg vaksinering ved anvendelse av levende vaksiner så vel som fremgangsmåter og midler som er anvendelige for vaksineringen. Slike fremgangsmåter og midler inkluderer fremgangsmåter for fremstilling av analoger og farmasøytiske preparater så vel som nukleinsyrefragmenter, vektorer, transformerte celler, polypeptider og farmasøytiske preparater.New methods are described for controlling diseases which are characterized by amyloid deposition. The methods generally relate to immunization against amyloid precursor protein (APP) or beta-amyloid (AP). Immunization is preferably performed by administering analogs of autologous APP or AP, said analogs being capable of inducing antibody production against the autologous amyloidogenic polypeptides. Particularly preferred as an immunogen is autologous AP which has been modified by introducing a single or a few foreign, immunodominant and promiscuous T cell epitopes. Nucleic acid vaccination against APP or AP is also described, and in addition vaccination using live vaccines as well as methods and agents useful for the vaccination. Such methods and agents include methods for preparing analogs and pharmaceutical compositions as well as nucleic acid fragments, vectors, transformed cells, polypeptides and pharmaceutical compositions.

NO20040431A 2001-08-20 2004-01-30 A pharmaceutical composition for down-regulation of amyloid containing an immunogen comprising a polyamino acid which induces production of antibody to the animal's autologous amyloid precursor protein (APP) or amyloid-beta (A-beta), nucleic acid fragment encoding the polyamino acid, vector and transformed cell. NO335602B1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DKPA200101231 2001-08-20
PCT/DK2002/000547 WO2003015812A2 (en) 2001-08-20 2002-08-20 Beta-amyloid-analogue-t-cell epitop vaccine

Publications (2)

Publication Number Publication Date
NO20040431L true NO20040431L (en) 2004-04-16
NO335602B1 NO335602B1 (en) 2015-01-12

Family

ID=35160895

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20040431A NO335602B1 (en) 2001-08-20 2004-01-30 A pharmaceutical composition for down-regulation of amyloid containing an immunogen comprising a polyamino acid which induces production of antibody to the animal's autologous amyloid precursor protein (APP) or amyloid-beta (A-beta), nucleic acid fragment encoding the polyamino acid, vector and transformed cell.

Country Status (10)

Country Link
EP (1) EP1363664A2 (en)
JP (1) JP2004529881A (en)
CN (1) CN100562338C (en)
AU (1) AU2002233166B2 (en)
CA (1) CA2440197A1 (en)
IL (1) IL157475A0 (en)
NO (1) NO335602B1 (en)
NZ (1) NZ527720A (en)
WO (1) WO2002066056A2 (en)
ZA (1) ZA200400895B (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003263150A1 (en) * 2002-09-12 2004-04-30 Pharmexa A/S Immunization against autologous ghrelin
AU2004281634B2 (en) * 2003-09-03 2011-01-27 Dendritherapeutics, Inc. Multiplex vaccines
US20070264280A1 (en) * 2003-11-07 2007-11-15 Federoff Howard J Compositions and Methods for Treating Neurological Diseases
AU2012229234B2 (en) * 2011-03-11 2016-02-25 Flow Pharma Inc. Vaccine formulation of mannose coated peptide particles
CN103665113A (en) * 2012-09-14 2014-03-26 深圳市安群生物工程有限公司 Human A beta 42 antigenic determinant polypeptide, human A beta 42 antigen, human A beta 42 antibody, application and kit
RU2635517C1 (en) * 2016-09-14 2017-11-13 Закрытое акционерное общество "Институт фармацевтических технологий" (ЗАО "ИФТ") Synthetic immunogen for protection and treatment of psychoactive substances addiction
CN112165956A (en) * 2018-04-10 2021-01-01 Ac免疫有限公司 Anti-abeta therapeutic vaccine

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE245446T1 (en) * 1992-02-11 2003-08-15 Jackson H M Found Military Med DUAL CARRIER FOR IMMUNOGENIC CONSTRUCTS
AU4377793A (en) * 1992-05-20 1993-12-13 Johns Hopkins University, The Alternative receptor therapy
IL141868A0 (en) * 1998-10-05 2002-03-10 M & E Biotech As Novel methods for therapeutic vaccination

Also Published As

Publication number Publication date
CA2440197A1 (en) 2002-08-29
CN100562338C (en) 2009-11-25
JP2004529881A (en) 2004-09-30
WO2002066056A3 (en) 2003-01-03
NO335602B1 (en) 2015-01-12
WO2002066056A2 (en) 2002-08-29
WO2002066056A8 (en) 2004-04-29
CN1893970A (en) 2007-01-10
AU2002233166B2 (en) 2006-06-29
ZA200400895B (en) 2005-05-03
IL157475A0 (en) 2004-03-28
EP1363664A2 (en) 2003-11-26
NZ527720A (en) 2005-03-24

Similar Documents

Publication Publication Date Title
NO20023961L (en) New method for down-regulation of amyloid
MY144532A (en) Novel method for down-regulation of amyloid
MXPA02007796A (en) Novel method for down regulation of amyloid.
WO2001005820A3 (en) Method for down-regulating gdf-8 activity
US9795666B2 (en) High-yield transgenic mammalian expression system for generating virus-like particles
WO2020193688A2 (en) Immunogenic compositions and vaccines comprising african swine fever virus peptides and proteins and uses thereof
NO20051779L (en) Immunization against autologous ghrelin
DE69716240T2 (en) NEW METHOD FOR VACCINATION AND VACCINE SUBSTANCES THAT CONTAIN AN EPITOP-CODING NUCLEIC ACID AND AN EPITOP-CONTAINING PEPTIDE
NO20040431L (en) New method for down-regulation of amyloid
US20080063664A1 (en) High-yield transgenic mammalian expression system for generating virus-like particles
US20090208522A1 (en) Neutralizing Epitope-Based Growth Enhancing Vaccine
JP2002510493A (en) DNA immunization against Chlamydia infection
AU2018386128B2 (en) Vaccine compositions and methods of making same
US11344614B2 (en) Pharmaceutical compositions comprising dengue virus-specific multiple HLA-binding T cell epitopes
MY135691A (en) Method for down-regulation of gdf-8 activity
Rouhollah et al. Immunological Evaluation of HIV-1 P24-Nef Harboring IFN-γas as an Adjuvant in BALB/c Mice
ECSP003580A (en) NEW METHODS TO INCREASE MUSCLE MASS THROUGH IMMUNIZATION AGAINST GDF-8

Legal Events

Date Code Title Description
MM1K Lapsed by not paying the annual fees